Eric Wickramasekara was an undergrad at MIT when he came up with the idea for a cloud-based Crispr design tool to help scientists. Eight years later, Regeneron, Gilead and hundreds of other companies use its collaborative R&D software, and the company boasts a roaster of investors that includes Andreessen Horowitz, Benchmark, Menlo Ventures, Thrive Capital, and Y Combinator. As many customers rush to come up with vaccines and treatments for Covid-19, Benchling is on call as needed—but has stopped pushing software updates to those whose projects require total lockdown.

Read more about the Next Billion Dollar Startups on Forbes:

Subscribe to FORBES:

Stay Connected
Forbes newsletters:
Forbes on Facebook:
Forbes Video on Twitter:
Forbes Video on Instagram:
More From Forbes:

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

How A Tool For Scientists Became A Billion-Dollar Opportunity | Forbes